Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Firebrick Pharma Limited ( (AU:FRE) ).
Firebrick Pharma Limited has received a $250,000 R&D Tax Incentive for its eligible R&D expenditure in the 2024/25 fiscal year. This funding supports the company’s ongoing development of Nasodine as a broad-spectrum antimicrobial agent and other new product initiatives, highlighting Firebrick’s commitment to innovation and its strategic positioning in the pharmaceutical industry.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine Nasal Spray and has introduced it to markets in the United States, Singapore, Fiji & South Pacific, with plans to launch in the Philippines in 2026.
Average Trading Volume: 91,862
Technical Sentiment Signal: Buy
For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.